CBD_SBIR_234_R1.PDF
PDF 167 KB Posted
- Attached to
- Decontamination of Open Wounds - Open Topic
- Solicitation number
- CBD234-P001
About this file
This document is a Chemical and Biological Defense (CBD) Small Business Innovation Research (SBIR) Program FY23.4 Proposal Submission Instructions announcement for an open topic solicitation. The proposal submission deadline is November 14, 2023 at 12:00 p.m. ET, with the Topic Q&A closing on October 31, 2023. Proposals must be submitted electronically through the Defense SBIR/STTR Innovation Portal (DSIP) at https://www.dodsbirsttr.mil. Phase I awards have a maximum funding cap of $197,283.00 for periods of performance up to six months. Phase II proposals may only be submitted by Phase I awardees no sooner than five months after Phase I contract award, with a 24-month period of performance and no maximum specified funding limit. The program targets small business concerns only, with restrictions limiting each small business to one proposal per open topic; multiple submissions result in only the most recent being evaluated.
The solicitation covers one open topic (CBD234-P001): Decontamination of Open Wounds, which seeks innovative man-portable capabilities to rapidly remove chemical warfare agents (CWAs) and toxic industrial chemicals (TICs) from both intact and wounded human skin under austere conditions. Key requirements include simplicity of field use, lightweight portability, rapid effectiveness across environmental conditions, FDA compliance, long shelf-life, ease of transportation, manufacturability, cost-effectiveness, and in-situ detoxification capability. Phase I proposals must not exceed 5 pages in technical volume with 10-point minimum font; companies must disclose all foreign nationals or dual citizens involved in the project. All proposers must complete mandatory Fraud, Waste, and Abuse training and submit required disclosure forms including certifications regarding telecommunications equipment, foreign affiliations, and funding sources. Failure to submit required disclosure forms automatically disqualifies applicants. The CBD SBIR Program reserves the right to limit awards and withdraw from negotiations; selection notifications will be provided within 90 days of the closing date, with debriefings available upon written request within 30 days of non-selection.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| CBD234-P001.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Cleared for Public Release
CBD SBIR Open Topic - 1
CHEMICAL AND BIOLOGICAL DEFENSE PROGRAM
FY23.4 Small Business Innovation Research (SBIR)
Proposal Submission Instructions
September 28, 2023: Topic issued for pre-release
October 12, 2023: CBD begins accepting proposals in DSIP
October 31, 2023: Topic Q&A closes to new questions at 12:00 p.m. ET
November 14, 2023: Deadline for receipt of proposals no later than 12:00 p.m. ET
The approved FY23.4 topics included in the Chemical and Biological Defense (CBD) Small Business
Innovation Research (SBIR) Program is provided in this document. Offerors responding to this
Announcement must follow all general instructions provided in the Department of Defense (DoD)
Program Announcement. Instructions detailing the CBD SBIR program requirements are provided below.
Proposers are encouraged to thoroughly review the DoD Program BAA and register for the DSIP
Listserv to remain apprised of important programmatic and contractual changes.
• The DoD Program BAA is located at: https://www.defensesbirsttr.mil/SBIR-
STTR/Opportunities/#announcements. Be sure to select the tab for the appropriate BAA cycle.
• Register for the DSIP Listserv at: https://www.dodsbirsttr.mil/submissions/login.
Please read the entire DoD Announcement and these CBD SBIR instructions carefully prior to submitting your proposal. Important programmatic changes have been incorporated as required by the SBIR and
STTR Extension Act of 2022 (Pub. L. 117-183). Also, go to https://www.sbir.gov/about/about-sbir#sbir-policy-directive to read the SBIR/STTR Policy Directive issued by the U. S. Small Business
Administration (SBA).
This release contains an open topic. As outlined in section 7 of the SBIR and STTR Extension Act of
2022, innovation open topic activities—
(A) Increase the transition of commercial technology to the Department of Defense;
(B) Expand the small business nontraditional industrial base;
(C) Increase commercialization derived from investments of the Department of Defense; and
(D) Expand the ability for qualifying small business concerns to propose technology solutions to meet the needs of the Department of Defense.
Unlike conventional topics, which specify the desired technical objective and output, open topics can use generalized mission requirements or specific technology areas to adapt commercial products or solutions to close capability gaps, improve performance, or provide technological advancements in existing capabilities.
A small business concern may only submit one (1) proposal to each open topic. If more than one proposal from a small business concern is received for a single open topic, only the most recent proposal to be certified and submitted prior to the submission deadline will receive an evaluation. All prior proposals submitted by the small business concern for the same open topic will be marked as nonresponsive and will not receive an evaluation.
INTRODUCTION
In response to Congressional interest in the readiness and effectiveness of U.S. Nuclear, Biological and
Chemical (NBC) warfare defenses, Title XVII of the National Defense Authorization Act for Fiscal Year
1994 (Public Law 103-160) requires the Department of Defense (DoD) to consolidate management and https://www.defensesbirsttr.mil/SBIR-STTR/Opportunities/%23announcements.
https://www.defensesbirsttr.mil/SBIR-STTR/Opportunities/%23announcements.
https://www.dodsbirsttr.mil/submissions/login https://www.sbir.gov/about/about-sbir#sbir-policy-directive https://www.sbir.gov/about/about-sbir#sbir-policy-directive
CBD SBIR Open Topic - 2 oversight of the Chemical and Biological Defense (CBD) Program into a single office – Office of the
Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense Programs. The Joint
Science and Technology Office for Chemical and Biological Defense (JSTO-CBD), located at the
Defense Threat Reduction Agency (DTRA), provides the management for the Science and Technology component of the Chemical and Biological Defense Program. Technologies developed under the Small
Business Technology Transfer (STTR) Program have the potential to transition to the Joint Program
Executive Office for Chemical Biological Radiological and Nuclear Defense (JPEO-CBRND) if the appropriate level of technology maturity is demonstrated. The JSTO-CBD Science & Technology programs and initiatives improve defensive capabilities against Chemical and Biological Weapons of
Mass Destruction. The SBIR portion of the CBD Program is managed by the JSTO-CBD.
The mission of the Chemical and Biological Defense Program is to ensure that the U.S. Military has the capability to operate effectively and decisively in the face of chemical or biological warfare threats at home or abroad. Numerous factors continually influence the program and its technology development priorities. Improved defensive capabilities are essential in order to mitigate the overall impact of chemical and biological threats. The U.S. military requires the finest state-of-the-art equipment and instrumentation available to permit our warfighters to ‘detect to warn’ and avoid contamination, if possible – and to be able to sustain operations in a potentially contaminated environment. Further information is available at the Office of the Assistant Secretary of Defense for Nuclear, Chemical, and
Biological Defense Programs homepage at https://www.acq.osd.mil/ncbdp/cbd/
The overall objective of the CBD SBIR Program is to improve the transition or transfer of innovative
Chem-Bio technologies to the end user – the warfighter – in addition to commercializing technologies within the private sector for mutual benefit. The CBD SBIR Program targets those technology efforts that maximize a strong defensive posture in a biological or chemical environment using passive and active means as deterrents. These technologies include chemical and biological detection for both point and stand-off capabilities; individual and collective protection; hazard mitigation (decontamination); medical pre-treatments (e.g., vaccine development and delivery); medical therapeutics (chemical countermeasures and biological countermeasures); medical diagnostics; Digital Battlespace Management (aka information systems technology) to include but not limited to modeling and simulation (e.g., meteorological dispersion), disease surveillance, data fusion, and health & human effects to include wearable technologies.
All proposals submitted to the CBD SBIR program must comply to the terms of this Announcement.
CBD SBIR reserves the right to limit awards under any topic, and only those proposals of superior scientific and technical quality, as determined by Technical Evaluation Team and the CBD SBIR program office will be funded. CBD SBIR reserves the right to withdraw from negotiations at any time prior to contract award. The Government may withdraw from negotiations at any time for any reason to include matters of national security (foreign persons, foreign influence or ownership, or other related issues).
Use of Foreign Nationals (also known as Foreign Persons), Green Card Holders, and Dual Citizens
See the “Foreign Nationals” section of the DoD SBIR Program Announcement for the definition of a
Foreign National (also known as Foreign Persons).
It is the responsibility of ALL offerors proposing to use foreign nationals, green-card holders, or dual citizens, to disclose this information regardless of whether the topic is subject to export control restrictions. Offerors MUST identify any foreign nationals or individuals holding dual citizenship expected to be involved on this project as a direct employee, subcontractor, or consultant. For these individuals, please specify their country of origin, the type of visa or work permit under which they are performing and an explanation of their anticipated level of involvement on the project. You may be asked https://www.acq.osd.mil/ncbdp/cbd/
CBD SBIR Open Topic - 3 to provide additional information during contract negotiations in order to verify the foreign citizen’s eligibility to participate on a SBIR contract. Supplemental information provided in response to this paragraph will be protected in accordance with the Privacy Act (5 U.S.C. 552a), if applicable, and the
Freedom of Information Act (5 U.S.C. 552(b)(6)).
Proposers responding to this Open Topic BAA must follow all general instructions provided in the
Department of Defense (DoD) SBIR Program BAA, paying special attention to the new requirements under the SBIR and STTR Extension Act of 2022 (Pub. L. 117-183). The Chemical and Biological
Defense SBIR Program requirements in addition to or deviating from the DoD Program BAA are provided in the instructions below.
Specific questions pertaining to the administration of the Chemical and Biological Defense SBIR
Program and these proposal preparation instructions should be directed to: Ms. Abigail L. Roots, Chemical and Biological Defense SBIR/STTR Program Manager, JSTO-CBD, at dtra.belvoir.rd.mbx.jsto-cbd-chem-bio-defense-sbir@mail.mil.
PHASE I PROPOSAL GUIDELINES
The Defense SBIR/STTR Innovation Portal (DSIP) is the official portal for DoD SBIR/STTR proposal submission. Firms are required to submit proposals via DSIP; proposals submitted by any other means will be disregarded. Detailed instructions regarding registration and proposal submission via DSIP are provided in the DoD SBIR Program BAA.
Proposal Coversheet (Volume 1)
The proposal coversheet must follow the instructions and requirements provided in the DoD SBIR
Program BAA.
The offeror shall certify that to the best of its knowledge and belief, its eligibility information under the
SBIR Program is accurate, complete, and current as of the date of the offer.
Technical Volume (Volume 2)
The technical volume is not to exceed 5-pages and must follow the formatting requirements provided in the DoD SBIR Program BAA. No other information included in the other proposal volumes counts against the 5-page Proposal Technical Volume page limit. Pages provided in excess of this length will not be evaluated or considered for review. The proposal must not contain any type smaller than 10-point font size (except as legend on reduced drawings, but not tables).
The maximum dollar amount for a Phase I proof-of-concept/feasibility study is $197,283.00 for a period of performance (PoP) of up to six (6) months. The CBD SBIR Program will not accept proposals exceeding $197,283.00 for the Phase I effort.
Your entire proposal submission must only be submitted electronically through the Defense
SBIR/STTR Innovation Portal (DSIP) located at: https://www.dodsbirsttr.mil. Any questions pertaining to the DoD SBIR/STTR submission system should be directed to DSIP Support:
DoDSBIRSupport@reisystems.com
Selection of Phase I proposals will be based upon the three (3) evaluation criteria discussed in this
Program Announcement. The CBD SBIR Program reserves the right to limit awards under any topic, and only those proposals of superior scientific and technical quality in the judgment of the technical evaluation team will be funded. All SBIR contract awards, both Phase I and Phase II, are subject to availability of funding.
mailto:dtra.belvoir.rd.mbx.jsto-cbd-chem-bio-defense-sbir@mail.mil https://www.dodsbirsttr.mil/ mailto:DoDSBIRSupport@reisystems.com
CBD SBIR Open Topic - 4
Companies should plan carefully for any research involving animal or human subjects, chemical agents, biological agents, etc. The brief PoP available for a Phase I project precludes plans that include these elements, as all DoD requirements and necessary approvals associated with animal and/or human use must be strictly adhered to, and require considerable coordination and significant time for final protocol approvals. See “Additional Information” below for further information regarding all research that will include animal and/or human subjects.
Proposals not conforming to the terms of this Announcement, and any unsolicited proposals, will not be considered. All awards are subject to the availability of funding and successful completion of contract negotiations. The Chemical and Biological Defense Program is not responsible for any funds expended by the proposer prior to contract award.
Cost Volume (Volume 3)
The Cost Volume must follow all instructions and requirements provided in the DoD SBIR Program
BAA. The Phase I Base amount must not exceed $197,283.00. Total Base cost for Phase I must be clearly identified on the Proposal Cover Sheet (Volume 1) and in Volume 3.
Company Commercialization Report (CCR) (Volume 4)
Completion of the CCR as Volume 4 of the proposal submission in DSIP is required. Please refer to the
DoD SBIR Program BAA for full details on this requirement. Information contained in the CCR will not be considered by the Chemical and Biological Defense Program during proposal evaluations.
Supporting Documents (Volume 5)
Offerors are welcome to provide Supporting Documents in this section, however these documents will not be considered by the Chemical and Biological Defense Program during proposal evaluations.
All proposing Small Business Concerns (SBC) are REQUIRED to submit the following documents to
Volume 5:
1. Contractor Certification Regarding Provision of Prohibition on Contracting for Certain
Telecommunications and Video Surveillance Services or Equipment
2. Disclosures of Foreign Affiliations or Relationships to Foreign Countries
3. Disclosure of Funding Sources
Please note, under the SBIR and STTR Extension Act of 2022 and the SBA SBIR/STTR Policy Directive, proposals are required to include additional forms, to include the SBA-approved “Disclosures of Foreign
Affiliations or Relationships to Foreign Countries” and “Disclosure of Funding Sources” forms.
NOTE: Failure to submit the above mentioned disclosure forms along with the proposal will automatically disqualify a SBC from receiving a SBIR award for that proposal.
Refer to the DoD Program BAA for more information.
DIRECT TO PHASE II PROPOSAL GUIDELINES
The Chemical and Biological Defense SBIR Program is not currently participating in any Direct to Phase
II topics.
PHASE II PROPOSAL GUIDELINES
Phase II proposals may only be submitted by Phase I awardees.
Phase II is the demonstration of the technology that was found feasible in Phase I. Phase I awardees may submit a Phase II proposal without invitation; however, it is strongly encouraged that a Phase II proposal
CBD SBIR Open Topic - 5 not be submitted until sufficient Phase I progress can be evaluated and assessed based on results of the
Phase I proof-of-concept/feasibility study. Therefore, Phase II proposal may be submitted no sooner than five (5) months from date of Phase I contract award. All Phase II proposal submissions must be submitted electronically through DSIP system: https://www.dodsbirsttr.mil
At the DSIP website, Phase II proposals MUST be submitted to ‘CBD SBIR’ regardless of which DoD contracting office negotiated and awarded the Phase I contract. Additional instructions regarding the
Phase II proposal submission process including submission key dates will be provided to Phase I awardees after the Phase I contract is awarded.
The Phase II proposal must include a concise summary of the Phase I project including the specific technical problem or opportunity addressed and its importance, the objective of the Phase I project, the type of research conducted, findings or results of this research, and technical feasibility of the proposed technology. Due to limited funding, the CBD SBIR program reserves the right to limit awards under any topic and only proposals considered to be of superior quality will be funded.
All proposers are required to develop and submit a commercialization plan describing feasible approaches for marketing and manufacturing the developed technology. Proposers are required to submit a budget for the entire 24-month Phase II Period of Performance. During contract negotiation, the Contracting
Officer may require a Cost Volume for a base year and an option year; thus, proposers are advised to be aware of this possibility. These costs must be submitted using the Cost Volume format (accessible electronically on the DoD SBIR/STTR submission site). The total proposed amount should be indicated on the Proposal Cover Sheet as the Proposed Cost. At the Contracting Officer’s discretion, Phase II projects may be evaluated for technical progress prior to the end of the base year, prior to extending funding for the option (second) year.
The CBD SBIR Program is committed to minimizing the funding gap between Phase I and Phase II activities. The CBD SBIR Program typically funds a cost plus fixed fee Phase II award at the discretion of the Contracting Officer, but may award a firm fixed price contract.
It is recommended that Phase II awardees have a Defense Contract Audit Agency (DCAA) approved accounting system. If you do not have a DCAA approved accounting system, this could delay/prevent a
Phase II contract award. Visit https://www.dcaa.mil/Customers/Small-Business for more information on
DCAA approved accounting systems.
DISCRETIONARY TECHNICAL AND BUSINESS ASSISTANCE (TABA)
At this time, the CBD SBIR Program is not participating in the Technical and Business Assistance
(TABA) Program.
EVALUATION AND SELECTION
All proposals will be evaluated in accordance with the evaluation criteria listed in the DoD SBIR Program
BAA.
Proposing firms will be notified of selection or non-selection status for a Phase I award within 90 days of the closing date of the BAA. Notification will be provided via e-mail to the small business offeror – specifically to the Corporate Official (Business Point of Contact) and the Principal Investigator, as listed on the Cover Page (Volume I) of the proposal.
Upon written request via e-mail sent to dtra.belvoir.rd.mbx.jsto-cbd-chem-bio-defense-sbir@mail.mil, and within 30-days of non-selection, debriefing statements will be provided by the CBD SBIR Program https://www.dodsbirsttr.mil/ https://www.dcaa.mil/Customers/Small-Business
CBD SBIR Open Topic - 6
Office. The debriefing statement will be provided only via reply e-mail to the Corporate Official and the
Principal Investigator, as listed on the Cover Page (Volume I) of the proposal. Requests from the offeror for further information after the debriefing statement will not be provided.
Refer to the DoD SBIR Program BAA for procedures to protest the Announcement.
As further prescribed in FAR 33.106(b), FAR 52.233-3, Protests after Award should be submitted to
Abigail L. Roots, Chemical and Biological Defense (CBD) SBIR Program Manager, Joint Science and
Technology Office for Chemical and Biological Defense (JSTO-CBD), dtra.belvoir.rd.mbx.jsto-cbd-chem-bio-defense-sbir@mail.mil.
ADDITIONAL INFORMATION
Fraud, Waste and Abuse
All offerors must complete the Fraud, Waste, and Abuse training (Volume 6) that is located on DSIP
(https://www.dodsbirsttr.mil). Please follow guidance provided on DSIP to complete the required training prior to submitting proposals.
To Report Fraud, Waste, or Abuse, Please Contact:
DoD Inspector General (IG) Fraud, Waste & Abuse
Hotline: (800) 424-9098 hotline@dodig.mil
Additional information on Fraud, Waste and Abuse may be found in the DoD Instructions of this
Announcement.
CBD SBIR Projects Requiring Animal Subjects
Refer to the DoD SBIR Program BAA for Research Involving Animal Subjects.
Companies should plan carefully for any research involving animal subjects, in addition to the use of any chemical or biological warfare agents, and use of any agents associated with “Dual Use Research of
Concern (DURC)”. The mandatory DoD level review of this research is typically a period of no greater than four (4) months.
Written authorization to begin animal research under the applicable protocol(s) proposed as part of the
CBD SBIR program will be issued after the contract award in the form of an approval memo from the
U.S. Army Medical Research and Development Command (MRDC), Animal Care and Use Review
Office (ACURO), and the Research Oversight Board (ROB) of the Defense Threat Reduction Agency
(DTRA), both of which provide DoD compliance oversight to the CBD SBIR program office.
The offeror is expressly forbidden from using or subcontracting for the use of animals in any manner prior to these approvals. Furthermore, modifications to approved protocols require review and approval by the ACURO prior to implementation.
Non-compliance with these terms and conditions may result in withholding of funds and/or the termination of the award. The ACURO and DTRA ROB reviews are separate from, and in addition to, the responsible Institutional Animal Care and Use Committee (IACUC) review(s). Further information may be required if the proposal is successful.
https://www.dodsbirsttr.mil/ mailto:hotline@dodig.mil
CBD SBIR Open Topic - 7
CBD SBIR Projects Requiring Human Subjects, Human Anatomical Substances, and/or Human Data
Refer to the DoD SBIR Program BAA for Research Involving Human Subjects and Recombinant DNA
Molecules.
Companies should plan carefully for any research involving human subjects, human data, and/or human biospecimens (human anatomical substances; e.g., blood, saliva, tissue), to include cadaveric specimens, hereafter referred to as “research”, in addition to the use of any chemical or biological warfare agents, and use of any agents associated with “Dual Use Research of Concern (DURC)”. The mandatory DoD level review of this research is typically no greater than four (4) months.
Projects under CBD SBIR awards involving the use of human subjects shall not be proposed for any
Phase I Period of Performance, but may be proposed during the Phase II Period of Performance.
Written authorization to begin the research under the applicable protocol(s) proposed as part of the CBD
SBIR program will be issued after the contract award in the form of an approval memo from the U.S.
Army Medical Research and Development Command (MRDC), Office of Human Research Oversight
(OHRO), and the Research Oversight Board (ROB) of the Defense Threat Reduction Agency (DTRA), both of which provide DoD compliance oversight to the CBD SBIR program office.
The offeror is expressly forbidden from beginning the research in any manner prior to these approvals.
Furthermore, modifications to approved protocols require review and approval by the OHRO prior to implementation.
Non-compliance with these terms and conditions may result in withholding of funds and/or the termination of the award. The OHRO and DTRA ROB reviews are separate from, and in addition to, the responsible Institutional Review Board (IRB) review(s). Further information may be required if the proposal is successful.
CBD SBIR Open Topic - 8
CBD SBIR 23.4 Topic Index
Release 1
CBD234-P001 Decontamination of Open Wounds – Open Topic
CBD SBIR Open Topic - 9
CBD234-P001 TITLE: Decontamination of Open Wounds – Open Topic
OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Biotechnology
OBJECTIVE: The purpose of developing an effective man-portable capability that will rapidly remove chemical warfare agents (CWAs) and other toxic industrial chemicals (TICs) of interest to the U.S.
Department of Defense from both intact and wounded human skin, under austere conditions is to bring potentially valuable small business innovations to the Chemical and Biological Defense Program portfolio to discover and develop chemical medical countermeasures (cMCMs) capable of neutralizing
CWAs in wounds and on the skin for the treatment of the Warfighter.
DESCRIPTION: Although decontamination issues have been studied since the onset of chemical warfare, decontamination of chemical warfare agents (CWAs) from the skin remains a thorny problem for a variety of reasons.
These include, first and foremost, the ability to rapidly and effectively remove a diversity of toxic chemicals that currently are, or could be, CWAs, without harming or damaging the contaminated skin or wound. Prompt and rapid post-exposure decontamination is critical to reduce the post-exposure effects of
CWAs.
In addition, a practical decontamination product needs to satisfy a plethora of secondary requirements, which include but are not limited to:
• Being simple to use in the field under harsh and likely confusing situations.
• Be light weight, compact, and easily stowed in a soldier’s pack.
• Be fast acting and effective under a wide range of environmental conditions.
• Meet and satisfy Federal Drug Agency (FDA) requirements.
• Meet and satisfy major DoD logistical requirements, i.e., long shelf-life, ease of transportation, manufacturability, and cost-effectiveness.
• Last, but not least, in addition to removing the toxic agents from skin, the product should be able to detoxify these chemical agents, both while it is being applied on the skin and after its removal.
Rapid agent detoxification and decontamination effectiveness are intricately linked because in-situ detoxification is an effective method of reducing agent concentration on the skin before the agent has time to diffuse into the sub-dermal region. Detoxification of the agent also attenuates or prevents secondary contamination of medical or other personnel, and of the environment.
Chemical warfare agents (CWAs) are among the most lethal and sinister substances manufactured by man (1). They are designed to kill, maim, immobilize, or psychologically threaten enemy troops.
CWAs can attack the skin which is not only the body’s interface with the outside environment, but also the largest organ of the body, with a surface area of roughly 1.6 m² for women and 1.8 m² for men (6).
Skin exposure to warfare agents is also a major problem during non- conventional war (5), or terrorist attack. Over the eons, a wide variety of materials in gas, liquid or solid form have been mobilized for this purpose. At present, CWAs of greatest concern in military operations are relatively low volatility organic liquids that attack the skin (vesicants) or attack the nervous system (nerve agents) (2-4).
Human skin, the largest human organ, developed as a physical barrier to the environment (to keep things out) but also maintains the aqueous nature of the human body (to keep things in). Mammalian skin consists of three major layers: stratum corneum, epidermis, and dermis. The stratum corneum, the thin outer layer of keratin-filled dead cells (corneocytes) bounded by densely crosslinked protein and embedded in crystalline lamellar lipids, represents the major barrier protecting the body from loss of internal components and entry of undesirable external materials. The stratum corneum, composed of
CBD SBIR Open Topic - 10 keratinized dead cells that are continually being replaced, is the first major barrier to chemical agents.
The layer underneath the stratum corneum, the epidermis, contains cells that differentiate from viable keratinocytes to corneocytes during their migration from the dermis to the stratum corneum. It also contains a large number of specialized cells. The dermis is the main component of living skin.
The purpose of decontamination is to reduce an initial amount of harmful material deposited on the surface of a person or object from the environment to a level that is low enough allow it to continue to safely function. It should be noted that permeability of the contaminant through the surface of the person or object is a complicating issue for any surface decontamination process. Contaminant permeability renders decontamination more difficult to perform, places time limitations on the window of opportunity for its performance.
The alternative to decontamination is discarding the object, which in the case of living beings, is not an option.
Current skin decontamination methods rely heavily on “wet” decontamination practices, which include washing the body with water, or soap and water (Roul et al., 2017). Alternatively, rapid decontamination makes extensive use of “dry” decontamination, which is based on adsorptive properties of powders, such as activated carbon or Fuller’s Earth (FE) (Roul et al., 2017).
Improved personal decontamination methods/products should consider:
• The effects on both intact skin and open wounds.
• Impacts on the subsequent wound healing process.
• Agent variable decontamination efficiency.
• Post-decontamination CWA detoxification capability. Rapid agent detoxification and decontamination effectiveness are intricately linked because in-situ detoxification is an effective method of reducing agent concentration on the skin before the agent has time to diffuse into the sub-dermal region. Post-decontamination detoxification of the contaminant(s)will also attenuate or prevent secondary contamination of medical or other personnel, and of the environment.
There is a clear need to develop an effective man-portable capability that will rapidly remove chemical warfare agents (CWAs) and other toxic industrial chemicals (TICs) of interest to the U.S. Department of
Defense from human skin, both intact and wounded, under austere conditions.
PHASE I: A feasibility study to demonstrate the technical and commercial practicality of the concept to include an assessment of its technical readiness and potential applicability to military and commercial markets.
PHASE II: Businesses will produce practical and feasible prototype solutions that can operate in edge and austere environments. Companies will provide a technology transition and commercialization plan for
Department of Defense and commercial markets. The DoD will evaluate each product in a realistic field environment and provide solutions to stakeholders for further evaluation. Based on Soldier field assessment, the DoD will request companies to update the previously delivered prototypes to meet final design configuration.
REFERENCES:
1. R.K. Gordon and E.D. Clarkson,(2009), “Rapid Decontamination of Chemical Warfare Agents”, Chapter 71, p. 1069 - 1081, Handbook of Toxicology of Chemical Warfare Agents”, CHAPTER 71
- Rapid Decontamination of Chemical Warfare Agents (prevor.com.cn) https://prevor.com.cn/wp-content/uploads/2021/06/Handbook_Gordon2010_rapid-decontamination_warfare-agents.pdf https://prevor.com.cn/wp-content/uploads/2021/06/Handbook_Gordon2010_rapid-decontamination_warfare-agents.pdf
CBD SBIR Open Topic - 11
2. K.J. Smith, K.J., et al. (1995). Sulfur mustard: its continuing threat as a chemical warfare agent, the cutaneous lesions induced, progress in understanding its mechanism of action, its long-term health effects, and new developments for protection and therapy. J. Am. Acad. Dermatol. 32: 765–76
3. C. Bismuth, C., et al. (2004). Chemical weapons: documented use and compounds on the horizon.
Toxicol. Lett. 149: 11–18
4. M. Ghanei and A.A. Harandi (2007). Long term consequences from exposure to sulfur mustard: a review. Inhal. Toxicol. 19: 451–6
5. S. Reutter, (1999). Hazards of chemical weapons release during war: new perspectives. Environ.
Health Perspect. 107: 985–90.
6. Surface Area of Human Skin - The Physics Factbook (hypertextbook.com).
7. G.K. Menon, (2002). New insights into skin structure: scratching the surface. Adv. Drug Deliv. Rev.
54: S3–17.
8. J. Hadgraft, and M.E. Lane (2005). Skin permeation: the years of enlightenment. Int. J. Pharmacol.
305: 2–12.
9. B. Godin, and E., Touitou, E. (2012). Dermal and Transdermal Delivery. In: Bhushan, B. (eds)
Encyclopedia of Nanotechnology. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9751-
4_81
10. H.I, Maibach, and R.C. Wester, “Percutaneous Absorption: In Vivo Methods in Humans and
Animals”, Journal of the American College of Toxicology. 1989;8(5):803-813.
doi:10.3109/10915818909018039
11. Handbook of Toxicology of Chemical Warfare Agents, 2009 Handbook of Toxicology of
Chemical Warfare Agents | ScienceDirect).
12. H.Z. Zhu, et al, “Effect of Soap-Water Wash on Human Epidermal Penetration”, pp. 87-99, Chapter
6, “Skin Decontamination”, H. Zhu and H.I. Mailbach, Ed., G. Springer Nature Switzerland, 2020 https://oi.org/10.1007/978-3-030-24009-7_6
13. A. Roul et al., “Fuller’s Earth Efficiency in Skin Decontamination”, pp. 121-139, Chapter 8 “Skin
Decontamination”, H. Zhu and H.I. Mailbach, Ed., G. Springer Nature Switzerland, 2020 https://oi.org/10.1007/978-3-030-24009-7_8
14. Fuller's Earth - Medical Countermeasures Database - CHEMM (hhs.gov)
15. (11) (PDF) ADSORPTION STUDIES OF FULLERS EARTH NANOCOMPOSITES FOR THE
REMOVAL OF COPPER AND REACTIVE YELLOW 18 (researchgate.net)
16. A. Roul et al., “Fuller’s Earth Efficiency in Skin Decontamination”, pp. 121-139, Chapter 8 “Skin
Decontamination”, H. Zhu and H.I. Mailbach, Ed., G. Springer Nature Switzerland, 2020 https://oi.org/10.1007/978-3-030-24009-7_8
17. S. Dachir, et al, « Fuller’s Earth: Old and Faithful Skin Decontamination Against Toxic Agents”, p.
101 -117, Chapter 7, “Skin Decontamination”, H. Zhu and H.I. Mailbach, Ed., G. Springer Nature
Switzerland, 2020 https://oi.org/10.1007/978-3-030-24009-7_7
18. M291 Skin Decontamination Kit | CCDC-CBC | MRIGlobal CBRNE Tech Index
19. U.S. DHS, CHEMM, “Reactive Skin Decontamination Lotion (RSDL) – Medical Counter Measures
Data Base ( 2017) Reactive Skin Decontamination Lotion (RSDL) - Medical Countermeasures
Database - CHEMM (hhs.gov)
20. E.H. Braue, Jr., et al, «Evaluation of RSDL, M291 SDK, 0.5% Bleach, 1% Soapy Water and
SERWACWA”, Part 1: Challenge with VX, USAMRICD-TR-09-01, U.S. Army Medical Research
Institute of Chemical Research, Aberdeen Proving Ground, MD 21010-5400, June 2009.
21. E.H. Braue, Jr., et al, «Evaluation of RSDL, M291 SDK, 0.5% Bleach, 1% Soapy Water and
SERWACWA”, Part2: Challenge with Soman, USAMRICD-TR-09-01, U.S. Army Medical
Research Institute of Chemical Research, Aberdeen Proving Ground, MD 21010-5400, July 2010.
22. I. Koplovitz, « Comparison of Four Skin Decontamination Procedures Using Reactive Skin
Decontamination Lotion (RSDL) Following Cutaneous VX Exposure in Guinea Pigs, USAMRICD-
TR-17-01, U.S. Army Medical Research Institute of Chemical Research, Aberdeen Proving Ground, MD 21010-5400, January 2016.
https://hypertextbook.com/facts/2001/IgorFridman.shtml https://www.sciencedirect.com/book/9780123744845/handbook-of-toxicology-of-chemical-warfare-agents https://www.sciencedirect.com/book/9780123744845/handbook-of-toxicology-of-chemical-warfare-agents https://oi.org/10.1007/978-3-030-24009-7_6 https://chemm.hhs.gov/countermeasure_fullersearth.htm https://www.researchgate.net/publication/350062903_ADSORPTION_STUDIES_OF_FULLERS_EARTH_NANOCOMPOSITES_FOR_THE_REMOVAL_OF_COPPER_AND_REACTIVE_YELLOW_18/figures?lo=1 https://www.researchgate.net/publication/350062903_ADSORPTION_STUDIES_OF_FULLERS_EARTH_NANOCOMPOSITES_FOR_THE_REMOVAL_OF_COPPER_AND_REACTIVE_YELLOW_18/figures?lo=1 https://oi.org/10.1007/978-3-030-24009-7_7 https://cbrnetechindex.com/p/6003/CCDC-CBC/M291-Skin-Decontamination-Kit https://chemm.hhs.gov/countermeasure_RSDL.htm https://chemm.hhs.gov/countermeasure_RSDL.htm
CBD SBIR Open Topic - 12
23. Emergent Biosolutions Inc., Resources – RSDL
24. Emergent Biosolutions Inc., RSDL – Reactive Skin Decontamination Lotion Kit
25. L. Taysse et al., 2007, Cutaneous challenge with chemical warfare agents in the SKH-1 hairless mouse (II): effects of some currently used skin decontaminants (RSDL and Fuller's earth) against liquid sulphur mustard and VX exposure - PubMed (nih.gov)
26. S. Tang et al, 2019, Hydrophilic scaffolds of oxime as the potent catalytic inactivator of reactive organophosphate - ScienceDirect
27. T.J. Walters, et al.,” Effect of reactive skin decontamination lotion on skin wound healing in laboratory rats”. Mil. Med. 172: 318–21 2007.
28. B.A. Mantooth et al, “Transport and Reactivity of Decontaminants to Provide Hazard Mitigation of
Chemical Warfare Agents from Materials”, ECBC-TR-1383, p. 2, June 2016
29. O. Koper, “The Development of FAST-ACT® by Nanoscale Corporation”, Chapter 14, pp 235-248, ACS Symposium Series, Vol. 1045, “Nanoscale Materials in Chemistry: Environmental
Applications”, edited by L.E. Erickson et al, 2010.
30. 30. Battelle Memorial Institute, “Determination of Surface Removal and Reactivity of Three Powder
Formulations with Selected Chemical Warfare Agents”, Final Report (Battelle Study No. 337-
G004762), June 2002.
31. P.W. Bartram and J.T. Lynn, Evaluation of FAST-ACTTM Formulations (Phase III, Test Service
Agreement No. 0219T), ECBC-TR-378, Edgewood Chemical Biological Center, Aberdeen Proving
Ground, MD 21010-5424, April 2004
32. A. Pinhal et al, 2021, (a_Andreia-Pinhal-EPA-2021.pdf (herts.ac.uk)).
33. H. H. Hill, Jr. and S.J. Martin, “Conventional analytical methods for chemical warfare agents”, Pure
Appl. Chem., Vol. 74, No. 12, pp. 2281–2291, 2002.
34. Ch. E. Kientz. “Chromatography and mass spectrometry of chemical warfare agents, toxins and related compounds: state of the art and future prospects”, J. Chromatogr. A814, 1–23 (1998).
35. J. R. Smith, M. L. Shih, E. O. Price, G. E. Platoff, J. J. Schlager. “Army medical laboratory telemedicine: Role of mass spectrometry in telediagnosis for chemical and biological defense”, J.
Appl. Toxicol.21, S35–S41 (2001).
36. “A Literature Review of Wipe sampling Methods for Chemical Warfare Agents and Toxic Industrial
Chemicals”, EPA/600/R-11/079 January 2007). Document Display | NEPIS | US EPA
37. S.A. Willison and et al, (2019) The imp(act of wipe sampling variables on method performance associated with indoor pesticide misuse and highly contaminated areas (nih.gov)
38. NIOSH Manual of Analytical Methods (NMAM), 5th Edition (2022) NMAM 5th Edition Web Book
| NIOSH | CDC
39. ASTM D6661-17, Standard Practice for Field Collection of Organic Compounds from Surfaces
Using Wipe Sampling, 2017
40. Karen Rossington, 2012 (The attraction of presat wipes (manufacturingchemist.com),
41. Karen Rossington, 2017 ( Methods for testing presaturated wipes (cleanroomtechnology.com),
42. Y. Liu et al, “Skin Exposure to Aliphatic Polyisocyanates in the Auto Body Repair and Refinishing
Industry: III. A personal Exposure Algorithm”, Ann. Occup. Hyg., 53 (1), 33-40, 2009
(Skin_Exposure_to_Aliphatic_Polyisocyanates_in_the_auto_body_industry, Y Liu et al 2008.pdf).
43. M. N. Richards, et al, “An approximate analytical approach to estimate the diffusivity of toxic chemicals in polymer barrier materials from the time evolution of sessile drop profiles”, Polymer
Bulletin, 76, 339–364, 2019, An approximate analytical approach to estimate the diffusivity of toxic chemicals in polymer barrier materials from the time evolution of sessile drop profiles | SpringerLink
KEYWORDS:
Decontamination; Chemical Warfare Agents; Personnel Decontamination; Casualty Decontamination;
Skin Decontamination; Open Wound Decontamination; Chemical Agent Detoxification
TPOC-1: Dr. Stephen Lee https://www.rsdl.com/resources/ https://www.rsdl.com/ https://pubmed.ncbi.nlm.nih.gov/20534641/ https://pubmed.ncbi.nlm.nih.gov/20534641/ https://pubmed.ncbi.nlm.nih.gov/20534641/ https://www.sciencedirect.com/science/article/abs/pii/S0009279718311323 https://www.sciencedirect.com/science/article/abs/pii/S0009279718311323 https://www.herts.ac.uk/__data/assets/pdf_file/0003/341193/a_Andreia-Pinhal-EPA-2021.pdf https://nepis.epa.gov/Exe/ZyNET.exe/P100E3WD.TXT?ZyActionD=ZyDocument&Client=EPA&Index=2006+Thru+2010&Docs=&Query=&Time=&EndTime=&SearchMethod=1&TocRestrict=n&Toc=&TocEntry=&QField=&QFieldYear=&QFieldMonth=&QFieldDay=&IntQFieldOp=0&ExtQFieldOp=0&XmlQuery=&File=D%3A%5Czyfiles%5CIndex%20Data%5C06thru10%5CTxt%5C00000032%5CP100E3WD.txt&User=ANONYMOUS&Password=anonymous&SortMethod=h%7C-&MaximumDocuments=1&FuzzyDegree=0&ImageQuality=r75g8/r75g8/x150y150g16/i425&Display=hpfr&DefSeekPage=x&SearchBack=ZyActionL&Back=ZyActionS&BackDesc=Results%20page&MaximumPages=1&ZyEntry=1&SeekPage=x&ZyPURL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045174/pdf/nihms-1553352.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045174/pdf/nihms-1553352.pdf https://www.cdc.gov/niosh/nmam/5th_edition_web_book.html https://www.cdc.gov/niosh/nmam/5th_edition_web_book.html https://www.manufacturingchemist.com/news/article_page/The_attraction_of_presat_wipes/79868 https://www.cleanroomtechnology.com/news/article_page/Methods_for_testing_presaturated_wipes/137011 file:///C:/Users/rkais/OneDrive/Documents/2022%20alt/Timilon/Skin%20Decontamination%20System/References%20-%20Other/Skin_Exposure_to_Aliphatic_Polyisocyanates_in_the_auto_body_industry,%20Y%20Liu%20et%20al%202008.pdf https://link.springer.com/journal/289 https://link.springer.com/journal/289 https://link.springer.com/article/10.1007/s00289-018-2382-2 https://link.springer.com/article/10.1007/s00289-018-2382-2
CBD SBIR Open Topic - 13
Phone: 919-308-7100
E-mail: stephen.j.lee28.civ@army.mil
File details come from the government source that posted it. Updated .